Refractory angina refers to a debilitating cardiovascular condition where patients suffer from chest pain or angina despite conventional medical treatment. The increasing prevalence of chronic cardiovascular diseases and the limitation of conventional treatment methods are key factors driving the demand for refractory angina therapies. Refractory angina treatments aim to enhance blood flow and provide relief from angina symptoms. Treatment options include enhanced external counterpulsation (EECP), spinal cord stimulation, and Renal Denervation. EECP utilizes intermittent compression of calves, thighs and buttocks to enhance blood flow and oxygen delivery. Spinal cord stimulation involves the use of electrodes embedded along the spinal cord to block pain signals. Renal Denervation uses radiofrequency energy to disable renal nerves and lower blood pressure in turn providing angina relief.
The Global Refractory Angina Treatment Market is estimated to be valued at USD 200.1 Mn in 2024 and is expected to reach USD 312.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Key Takeaways
Key players operating in the Refractory Angina Treatment Market are Boston Scientific Corporation, Medtronic, St. Jude Medical, Neuravi, and MicroPort Scientific Corporation.
The rising cases of debilitating chronic angina along with the limitations of coronary bypass and angioplasty procedures are creating growth opportunities for novel refractory angina treatment technologies. Further advancements in minimally-invasive therapies, renodal denervation and stem cell therapy hold promise.
Major players are focused on expanding their geographic presence across countries with high heart disease burden like the US, China, Japan and India. Partnerships with hospitals, promotion of clinical trials and reimbursement policies are supporting market growth globally.
Market drivers
The increasing prevalence of cardiovascular diseases and lack of effectiveness of conventional treatments in relieving symptoms of refractory angina are driving demand. Growing geriatric population vulnerable to chronic heart conditions also support market growth. Further, availability of reimbursement for refractory angina therapies in developed markets encourages adoption. Research into combinational therapies utilizing EECP, SCS and renal denervation holds potential to offer enhanced relief, boosting the refractory angina treatment market.
PEST ANALYSIS
Political: The governments regulations related to drug approval and clinical trials might impact the market.
Economic: The rise in healthcare expenditure has stimulated the demand for advanced refractory angina treatment in the market.
Social: Growing awareness about cardiac diseases and availability of treatment options are positively impacting the market.
Technological: Developments in drug delivery systems and new drug formulations for refractory angina are fueling the market growth. Advanced technologies help physicians to better diagnose and monitor refractory angina patients.
Geographical regions with market concentration
North America holds a significant share of the refractory angina treatment market, owing to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and high healthcare expenditure. The growing prevalence of cardiac diseases also contributes to the large share of the North American region. Asia Pacific is expected to showcase lucrative growth opportunities due to the improving healthcare facilities and increasing disposable incomes.
Fastest growing regional market
Asia Pacific refractory angina treatment market is poised to witness the highest growth during the forecast period. Factors such as the rising geriatric population, improving access to healthcare, and growing awareness about cardiac care will support the market expansion in Asia Pacific. Initiatives by governments to increase healthcare spending also play a crucial role in facilitating the treatment uptake. These favorable conditions are likely to boost the Asia Pacific refractory angina treatment market in the upcoming years.
Author Bio:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)